Preview

Epilepsy and paroxysmal conditions

Advanced search

Submissions

Online Submissions

Already have a Username/Password for Epilepsy and paroxysmal conditions?
Go to Login

Need a Username/Password?
Go to Registration

Registration and login are required to submit items online and to check the status of current submissions.

Start submission
 

Author Guidelines

1.      General Requirements

1.1.        Introduction

In the course of preparation, submission to the editorial board, reviewing and pre-publication preparation of submissions the authors should adhere to the "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals" of the International Committee of Medical Journal Editors, ICMJE

 

1.2.        General criteria

1.2.1. The General criteria for the publication of articles in the journal “Epilepsy and Paroxysmal Conditions” are the relevance, novelty of the material and its value in theoretical and/or applied aspects.

1.2.2. The manuscript is accepted for further consideration only if it has not been submitted to any other journals, published in the Internet or published previously.

 

1.3.        Language

Manuscripts submitted for publication in the journal “Epilepsy and Paroxysmal Conditions” should be written in Russian or English and comply with the scope of the journal.

 

1.4.        File requirements

1.4.1.  Please upload your manuscript as a Microsoft Office Word (MS Word) document (*.doc, *.docx and *.rtf formats).

1.4.2.  An article should be typed using the Times New Roman font (12 points; one-and-a-half spacing;  2 cm top, bottom, right and left margins).

 

1.5.        How to submit

Manuscripts are accepted in electronic format only: via online submission form in the “Epilepsy and Paroxysmal Conditions” journal website and by e-mail info@irbis-1.ru. Editorial Office tel: +7(495)6495495

 

1.6.        Types of manuscripts

1.6.1.  Original articles present the study results. The page limit is 13-18 MS Word pages (including references, tables, and figure legends). The minimal number of references is 15. The structured summary (abstract) should contain 5 sections (Background or Introduction, Aim, Material and Methods, Results, Conclusion, and Key words), and be no longer than 300 words.

1.6.2.  Review Articles are papers that written based on existing original articles and contains the summary of scholarly research and analysis on certain topics. The page limit is 16-23 MS Word pages (including references, tables, and figure legends). The maximal reference number is 100. The structured or non-structure summary (abstract) should be no longer than 300 words.

1.6.3.  Lectures, or clinically oriented reviews, are written by experts in broader areas of medicine. Lectures could be focused on diagnostics, treatment, prevention, pharmacology, epidemiology, pathophysiology, evaluation of outcomes and HTA aspects. The page limit is 16-23 MS Word (including references, tables, and figure legends). The maximal reference number is 80. The structured or non-structure summary (abstract) should be no longer than 300 words.

1.6.4.  Case Reports are a brief reports on a complex diagnostic problem and its solution, or a description of a rare clinical observation. The page limit is 12-16 MS Word pages (including references, tables, and figure legends). The minimal number of references is 6. The structured or non-structure summary (abstract) should be no longer than 150 words.

1.6.5.  Short Communications article is short format for presentation of opinions on the problem or results of scientific research; no more than 10-12 MS Word pages, no more than 2 figures or tables, at least 6 references.

1.6.6.  Letters to the Editor is open postpublication feedback of an article, often critical of some aspect of the original paper. Any reader can share his opinions on the article. The feedback have sent to the corresponding author of the original article. The authors of the original article can respond to these with a letter of their own. Peer-review process is required for any Letter to the Editor before publishing.

 

1.7.        Recommendations for original articles

1.7.1. International standards and guidelines. The Editors recommend* that manuscripts should be completed in accordance with internationally recognized standards of good publication practices:

1.7.1.1. Randomized trials – recommendations of CONSORT (Consolidated Standards Of Reporting Trials). The list of obligatory sections of the submission is posted here, a sample of diagram describing the sequence of conduction of the randomized trial is here.

1.7.1.2. Non-randomized comparative studies – recommendations of TREND (Transparent Reporting of Evaluations with Nonrandomized Designs).

1.7.1.3. Observational Studies (cohort, case-control, cross) – recommendations of STROBE (Strengthening the Reporting of Observational Studies in Epidemiology). The list of obligatory sections of the submission is posted here. A tailored version is posted here.

1.7.1.4. Diagnostic studies – recommendations of STARD (Standards for Reporting of Diagnostic Accuracy).

1.7.1.5. Prognostic studies – recommendations of TRIPOD (The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis).

1.7.1.6. Systematic reviews and meta-analyses – recommendations of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The list of obligatory sections is posted here, the scheme of the systematic search - here.

1.7.1.7. Economic assessment of medical interventions – recommendations of CHEERS (Consolidated Health Economic Evaluation Reporting Standards).

 

1.8.        Publication of uncontrolled clinical trials results

1.8.1.  An uncontrolled trial is a research without control group.

1.8.2.  Articles based on uncontrolled trials results will be accepted for publication if the uncontrolled design of the study is mentioned in “Material and methods” and “Discussion” sections. It is important not to exaggerate significance of the obtained results in the “Conclusion” section.

 

1.9.        Ethical aspects

1.9.1.  Trials should be held in accordance with the main principles of "Good Clinical Practice”. Participants of a trial should be informed about the purposes and main aims. They must sign their written informed consent to participate in the trial. The «Material and methods» section must contain details of the above-stated procedure, and notification that Ethical Committee has approved the trial report. If a trial includes radiological methods, it is desirable* to describe these methods and exposition doses in the «Material and methods» section.

1.9.2.  Where a description of human studies is provided in the manuscript, it must be stated whether it met the ethical standards of the Ethical Committee (member of the institution in which the work was carried out or regional) or The 1975 Declaration of Helsinki and its revision in 2000.

1.9.3.  Patients have the right to privacy and confidentiality of their personal data. Therefore, information containing pictures, names, and initials of patients or numbers of medical documents should not be presented in the materials. If such information is needed for scientific purposes, it is necessary to get written informed consent of the patient (or the parent, the trustee, close relatives when it is applicable) for its publication in print or electronically. If necessary, written consent should be presented to the Editors at request.

1.9.4.  Animal trials must conform to the International Guiding Principles for Biomedical Research Involving Animals, adopted by the Council for International Organizations Of Medical Sciences (CIOMS) in 1985.

 

1.10.      Authorship

1.10.1.  Each author should significantly contribute to the work submitted for publication.

1.10.2.  All members of the group of authors should meet all four criteria of authorship set forth in the ICMJE recommendations:

1) concept and design development or data analysis and interpretation

2) manuscript justification or verification of critical intellectual content

3) final approval for publication of the manuscript

4) consent to be responsible for all aspects of the work and assume that issues relating to the thoroughness and diligent execution of all parts of the study submitted are duly investigated and resolved (even ones in which the author was not personally involved).

1.10.3. Participation in data gathering only does not justify the authorship (such participation should be noted in the “Acknowledgements” section).

 

1.11.      Corresponding Author

1.11.1.  The journal does not require all authors of a manuscript to sign the letter of submission, nor do they impose an order on the list of authors. Submission to the journal is taken by the journal to mean that all the listed authors have agreed all of the contents, including the author list and author contribution statements.

1.11.2.  The Corresponding Author is responsible for having ensured that this agreement has been reached that all authors have agreed to be so listed, and have approved the manuscript submission to the journal, and for managing all communication between the journal and all co-authors, before and after publication.

1.11.3.  The Corresponding Author is also responsible for submitting a competing interests' statement on behalf of all authors of the paper.

1.11.4.  It is expected that the corresponding author will be responsible for the following with respect to data:

• ensuring that data comply with transparency and reproducibility standards;

• ensuring that original data upon which the submitted manuscript is based are preserved following best practices in the field so that they are used for reanalysis;

• confirming that data presentation accurately reflects the original;

• foreseeing and minimizing obstacles to the sharing of data described in the work

• ensuring that all authors (or group leaders in multi-center collaborations) have certified the author list and author contributions

1.11.5.  At submission, the Corresponding Author must include written permission from the authors of the work concerned for mention of any unpublished material cited in the manuscript (for example others' data in press manuscripts; personal communications or work in preparation).

1.11.6.  The Corresponding Author also must clearly identify at submission any material within the manuscript (such as figures) that has been published previously elsewhere and provide written permission from authors of the prior work and/or publishers, as appropriate, for the re-use of such material.

1.11.7.  The Corresponding Author, submitting the manuscript to the Editor, assigns the Editor to publish it. The Editors have the right to provide the manuscript with any illustrated or text material, including advertisements. The Editors allow the third parties to put such content into the manuscript.

1.11.8.  Submission of the manuscript to the Editors implies that the Corresponding Author since moment of submission via online form or sending e-mail to the Editorial agrees to transfer the exclusive property rights for the manuscript and other objects of the copyright, like photos, drawings, schemes, tables, etc. to the Editors. The Editors obtain the right to reproduce (partly or fully) all the content submitted, including objects of the copyright, in press and on Internet; to distribute; to translate the manuscript and other provided content into any language of the world; to export and import copies of the issue where the article of the Author was published; to revise the manuscript.

1.11.9.  The Corresponding Author transfers the rights specified in clauses 1.11.7. and 1.11.8. to the Editors without any time limitations or territory restrictions, including the territories of the Russian Federation.

1.11.10. The Editors have the right to transfer the rights received from the author to the third party or to prohibit any use of materials published in the journal by the third party.

1.11.11. The Corresponding Author guarantees that he or she holds the all authors rights to all materials submitted to the editorial office. In case of violation of this guarantee by the Corresponding Author and consequent claims to the Editors, the Corresponding Author is obliged to settle all the claims at his/her own expense. The Editors are not responsible for the guarantee’s violation by the Corresponding Author.

1.11.12. The Authors retain the right to use the published material or its parts for personal needs, including scientific and educational purposes.

1.11.13. Manuscripts can be reviewed by independent experts. All manuscripts are reviewed on the double-blind reviewing basis - neither the Authors know who reviewers are, nor the reviewers know who the Authors of each particular manuscript is. The name of institution, where the Author works or makes research remains confidential as well.

1.11.14. Reviewers’ comments and opinions can be sent to the Corresponding Author for making changes or corrections. Time for corrections or reasoned objections is not less than 2 weeks. In case of untimely answer of the Corresponding Author the Editors have the right to make their own independent scientific editing and to make corrections to the publication or to refuse to publish the article. Editing, shortening and correction of the manuscript, and changes in the graph, picture or table design are made in order they comply the standards of the Journal. The meaning of the submitted content should not be changed after corrections. To add and (or) delete the references it is necessary to receive confirmation of the author by e-mail.

1.11.15. The Editors are not responsible for reliability of the information presented in the manuscripts.

1.11.16. In case the author does not agree with the comments or refusal to publish, a discussion is possible. The author's arguments to be sent to the reviewers and the Editor-in-chief and can be publish together with the peer-review as Letter to the Editor.

 

1.12.      Conflict of interests/funding

1.12.1. It is necessary for authors to disclose (in a covering letter or on the title page) any possible relationships with industrial and financial organizations, which can lead to a conflict of interests with regard to the content of the article.

1.12.2. It is also desirable to list all sources of financing in a footnote on the title page.

 

1.13.      Checking for plagiarism and self-plagiarism

1.13.1. All manuscripts are automatically checked by the "Antiplagiat" service.

1.13.2. Minimum allowed level of originality is 85% (taken into account that standard techniques can be described in the “Materials and methods” section and references can be duplicated). Only manuscripts with an originality level more than 85% are accepted for further consideration and peer review.

1.13.3. To avoid time wasting before article submission to the journal it should be independently checked for plagiarism. The TEXT.RU  https://text.ru/antiplagiat provides this service free of charge for sources in Russian language.

 

2.      Structure of manuscript

2.1.        Manuscripts should be organized as follows:

1)  Title page;

2)  Structured summary and keywords;

3)  Text;

4)  Acknowledgements (if applicable);

5)  List of references;

6)  Diagrams, charts, drawings, tables

7)  Statement on data sharing (if applicable)

 

2.2.        Title page. Title page includes:

• Title of Manuscript

• Authors information

• Declaration about conflict of interests/funding

• Declaration about author’s contribution

• Obligatory confirmation

2.2.1. Title of Manuscript should include the article title in Russian and English.

2.2.1.1. Best article titles bear short, clear and distinctive messages

2.2.1.2. The English title should be competent from the point of view of the English language, while the meaning is fully consistent with the Russian name.

2.2.1.3. Please, use international nonproprietary names (INN) of drugs in the title. Exceptions are possible when usage of trade names is well-grounded (for example, in studies of bio- or therapeutic equivalence of drugs).

2.2.2. Authors information

2.2.2.1. Authors information includes full given names and last names of the authors, the full name of the institution(s) from which the manuscript came, its(their) full mail address(es) with postal code. The name(s) of the author(s) should also be submitted in the author’s approved English spelling. The name(s) of the institution should also be submitted in the authorized English spelling.

2.2.2.2. Authors information also includes the author’s scientific degrees and titles, positions at the institution from which the manuscript came. The names of units, in which the authors work (chair, department, laboratory, etc.) must be submitted in the authorized English spelling or should be pointed out that the official spelling is absent.

2.2.2.3. Specify the contact information of the Corresponding Author (with editorial board, readers). The section should contain the following:

• Full name

• academic degree

• academic title

• position

• structural unit and full name of organization (primary employment)

• postal address (with zip code)

• e-mail address

• business phone number (with area code)

• mobile number (required for hot link with the author, in the published version of the manuscript is not indicated).

2.2.2.4. In addition, be sure to list the mobile numbers and email addresses of ALL co-authors.

2.2.2.5. It is strongly recommended (for the benefit of authors) to specify the individual investigator codes, which can be obtained at registration in the ORCID, Scopus, ResearcherID.

Example

Makatsariya A.D.

ORCID: https://orcid.org/0000-0001-7415-4633  

Scopus Author ID: 8305171100

https://www.scopus.com/authid/detail.uri?authorId=6602363216   

ResearcherID: C-6184-2013

https://publons.com/researcher/2224042/alexander-d-makatsariya/  

 2.2.3. Declaration about conflict of interests/funding

2.2.3.1. Statement of the presence or absence of a conflict of interest in the preparation of this article (example: “The authors declare about the absence of conflict of interest with respect to this publication.”)

2.2.3.2. Statement that this study was supported/funded by the company.

2.2.4. Declaration about author’s contribution

2.2.4.1. Example 1: “Author 1 - model development, analysis and interpretation of results, writing text; Author 2, Author 3  - writing text, editing, final approval of the manuscript.”

2.2.4.2. Example 2: “all authors contributed equally to the article”.

2.2.5. Obligatory confirmation

2.2.5.1. The authors must confirm that the article has not been published or submitted for publication elsewhere (or an explanation of this should be provided in the Comments for the editor).

2.2.2.2. The authors must confirm that all of them have read and approved the final version of the manuscript

 

2.3.        Structured summary (abstract) and keywords

2.3.1.  The text of summary for the original articles with study results  should contain the following sections: “Introduction”, “Aim”, “Material and methods”, “Results”, and “Conclusion”.

2.3.2.  In the summary of the review article it is necessary to reflect its main goal, briefly characterize used sources of data and present the main conclusion/conclusions of the review. A manuscript must contain all data presented in summary.

2.3.3.  Summary of the case study should reflect the main description of the case, the reasons for presenting this particular case and the content of the overview part.

2.3.4.  In addition to the text of summary in Russian it is necessary to submit its full translation into English. 5-8 keywords of the article should be given at the end of the abstract.  MeSH (Medical Subject Headings) thesaurus is a preferred source for choosing keywords.

2.3.5.  If the article and summary/key words in English, translation in Russian not necessary.

 

2.4.        Text

2.4.1.  Text of original article should contain the following sections:

•    Introduction (reflecting an urgency of a problem and research goals);

•    Aim

•    Materials and methods;

•    Results;

•    Discussion of the obtained results

•    Conclusion.

The text should be clear, brief and without repeating.

2.4.1.1. Introduction - brief description of the problem, which was the immediate cause of the study. Scale, indirect effects and/or continuing gaps in knowledge may be the characteristics of the problem.

2.4.1.2. Aim should describe the main (primary) goal of the study, the issue for the resolution of which a study is required. Moreover, the aim should be very specific and not be limited to overall comparison.

2.4.1.3. Materials and methods – this abstract section should contain brief information on:

•    Study subjects (healthy, sick, data),

•    Experimental groups,

•    Inclusion and exclusion criteria,

•    Ethical aspects,

•    Availability and characteristics of intervention,

•    Study site,

•    Study duration,

•    Methods of outcomes evaluation.

•    Statistics methods

2.4.1.4. All submitted materials can be revised to ensure relevance and accuracy of statistical methods and statistical interpretation of results. The “Material and methods” section should contain a subsection with detailed description of statistical methods, including those used for generalization of data; and of methods used for testing hypotheses (if those are available). Significance value for testing hypotheses must be provided. Please indicate statistical software which was used to process results and its version if you use more complex statistical methods (besides a t-test, a chi-square, simple linear regression).

2.4.1.5. Study results - section should contain a brief description of study subjects (number included in the study, completed its most significant characteristics of participants) with the assessment of study outcomes related to its purpose. Presentation of study outcomes in the limited number of subgroups (up to 2-3) is allowed, for example, outcomes formed on the basis of sex, age, important characteristics of the disease. If there is data on adverse events related to medical intervention, their mention is obligatory. The results of the statistical analysis (р-value) must be represented with accuracy to the third decimal place. In the analysis of multi-criteria relationships (the simplest option is one dependent and several independent variables) representation of the results of the multivariate analysis is required.

2.4.1.6. Discussion - author's interpretation of the obtained results and comparison with the data of previous studies. A section can be combined with the “Study results” section and called “Study results and discussion”.

2.4.1.7. Conclusion – short (1-2-3 sentences) summarizing of study outcomes relating to its main (primary) objective. Authors should avoid over-generalizations and stick to the balance in the assessment of the positive and negative effects of intervention.

2.4.2.  Review articles, Case Reports, and Lectures may be unstructured, but it is desirable to include the following paragraphs: “Introduction”, “Aim”, “Materials and methods”, “Results”, “Discussion” and “Conclusion” (“Recommendations”) into the text.

2.4.3.  You should provide titles and subtitles in the sections: “Material and methods”, “Results” and “Discussion”.

2.4.4.  Each reference, image or table should be numbered and specified in order of appearance in the text. References in the text must be numbered in Arabic figures and provided in square brackets.

2.4.5.  Each image, chart, table, photo, and reference must be indicated in order of appearance in the text.

2.4.6.  The titles to the image, chart, table, photo, should be in Russian and English languages both.

2.4.7.  All units of measure should be provided in SI system. No abbreviations, except standard abbreviations of chemical and mathematical terms, are acceptable.

 

2.5.        Acknowledgements and others

2.5.1.  Acknowledgements section may be presented in Russian, English or both languages. If the submitted material has contributors who do not meet the criteria of authorship, but have made some contribution to the work, they should be listed in this document and at the end of the article in the section of Acknowledgements.

2.5.2.  Acknowledgements section could comprise the following:

2.5.2.1. Clarification regarding any potential or actual conflicts of interest of the authors. Please note that conflicts of interest do not impede a publication, though failure to disclose one does.

2.5.2.2. A brief list of funding sources for the results reported in the paper, as well as the publication process itself (e.g. a commercial organization, a foundation or government grant, etc.).

2.5.2.3. You may also place here an acknowledgment for any individuals or organizations that assisted in your work.

2.5.3. The Acknowledgements section should not exceed 100 words.

2.5.4.  At the end of manuscript, it’s desirable to mention:

1) Highlights

  • What is already known about this subject? (2-3 points each till 30 words)
  • What are the new findings? (1-3 points each till 30 words)
  • How might it impact on clinical practice in the foreseeable future? (1-3 points each till 30 words)

2) Funding

3) Restrictions (if any)

4) Patient consent for publication (for clinical trials only, examples below or write your version):

Example 1 - “Not required “; Example 2 - “Obtained”

5) Ethics approval:

Example 1 - “Not required “; Example 2 - “Obtained”

6) Provenance and peer review (examples below or write your version):

Example 1: “Not commissioned; externally peer reviewed”

 

2.6.        List of References

2.6.1.  Please use separate sheet for the list of references. Give each source a consecutive number and start it with the new line. The list of references should be composed in order of citation. Use Index Medicus to search for abbreviations of the names of journals.

2.6.2.  All documents referred to in the text, should be included into the list of references or footnotes.

2.6.3.  If the manuscript is in Russian. In order to increase the quotation of authors, transliteration (translation of the Cyrillic script into the Latin alphabet) of Russian-language sources using official encodings is mandatory in the following order: authors and the name of the journal are transliterated using encodings, and the title of the article – a semantic translation into English. If a source has an original transliteration, the latter is used. You can use online services: http://translit.ru (basic) for making transliteration. Below there are examples of the transliteration of Russian-language (Cyrillic) sources into the Latin alphabet.

2.6.4.  Authors are responsible for accuracy of information provided in the list of references.

2.6.5.  The list of references should correspond to format recommended by the American National Information Standards organization – NISO, adopted by the National Library of Medicine (NLM) for databases (Library's MEDLINE/PubMed database) NLM: https://www.ncbi.nlm.nih.gov/books/NBK7256/

2.6.6.  If an article cited has a DOI (digital object identifier – a unique digital identifier of an article in the CrossRef system) it must be stated in the bibliography. DOI can be found at http://search.crossref.org/ (enter the title of the article in English in the search box).

2.6.7.  Two Reference lists must be provided for Russian-language manuscripts:

•    Literature [all publications in the native language (Russian words – in Cyrillic characters, foreign words – in Latin characters)] (GOST R 7.0.5 2008);

•    References [authors’ last names, names of publication sources and publishers are transliterated, name of the publication – book, article, thesis – is translated into English, the language of the publication is stated in parentheses (In Russ.)].

2.6.8.  The bibliography must not contain manuscripts (including theses), unpublished materials and guidebooks as well as regulatory documents. These sources must be listed in footnotes and contain the name of the document and its author (if applicable), location of the document (organization or depository), for regulatory documents –issuing authority, date, number, title.

2.6.9.  Bibliography examples:

A Russian-language article citation

Косолапов Е. Г., Коченков Ф. С., Погудина Н. Л., Блинов Д. В. Клинико-экономический анализ применения комбинированного препарата вилантерол + умеклидиния бромид для терапии хронической обструктивной болезни легких тяжелого и крайне тяжелого течения по сравнению с монотерапией препаратом тиотропия бромид. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2017; 10(2): 31–40. DOI: 10.17749/2070-4909.2017.10.2.031-040.

Kosolapov E. G., Kochenkov F. S., Pogudina N. L., Blinov D. V. Cost-effectiveness of vilanerol / umeclidinium versus tiotropium in severe and very severe copd. FARMAKOEKONOMIKA. Modern pharmacoeconomics and pharmacoepidemiology. 2017; 10(2): 31–40. (In Russ.) DOI: 10.17749/2070-4909.2017.10.2.031-040.]

A foreign language article citation

Sarno L., Tufano A., Maruotti G.M. et al. Eculizumab in pregnancy: a narrative overview. J Nephrol. 2019;32(1):17–25. DOI: 10.1007/s40620-018-0517-z.

Books and monographs citation

Бицадзе В.О., Макацария А.Д., Стрижаков А.Н., Червенак Ф.А. Жизнеугрожающие состояния в акушерстве и перинатологии. M.: МИА, 2019. 672 с.

Bitsadze V.O., Makatsariya A.D., Strizhakov A.N., Chervenak F.A. Life-threatening conditions in obstetrics and perinatology. [Zizneugrozhayushchie sostoyaniya v akusherstve i perinatologii]. Moskva: MIA, 2019. 672 s. (In Russ.).

Murray P.R., Rosenthal K.S., Kobayashi G.S., Pfaller M.A. Medical microbiology. 4th ed. St. Louis: Mosby, 2002.

Chapter in the book citation

Chang K.M. Immune pathogenesis of viral hepatitis B and C. In: Zakim and Boyer's hepatology: a textbook of liver disease. Eds. D. Boyer, M.P. Manns, A.J. Sanyal. 6th ed. Saunders, 2012. 111–28.

Electronic resources citation

Данные о предельных размерах оптовых надбавок и предельных размерах розничных надбавок к ценам на жизненно необходимые и важнейшие лекарственные препараты, установленные в субъектах Российской Федерации (данные за 3 квартал 2017 г.). ФАС России.  [Электронный ресурс]. Режим доступа: https://fas.gov.ru/documents/665519. Дата обращения: 06.10.2018.

Data on the limits of wholesale mark-ups and the limits of retail mark-ups on the prices of vital and essential drugs established in the constituent entities of the Russian Federation (data for the 3rd quarter of 2017). FAS Russia. [Electronic resource]. Available at: https://fas.gov.ru/documents/665519. (in Russ.). Accessed: 06.10.2020.

Legislative documents citation

Федеральный закон от 21.11.2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации». Официальный интернет-портал правовой информации. [Электронный ресурс]. Режим доступа: http://www.pravo.gov.ru. Дата обращения: 07.03.2020.

Federal Law of 21.11.2011, No. 323-ФЗ “On the basis of the protection of public health in the Russian Federation”. Official Internet portal of legal information. [Electronic resource]. Available at: http://www.pravo.gov.ru. (in Russ.). Accessed: 07.03.2020

Veterans Hearing Loss Compensation Act of 2002, Pub. L. No. 107-9, 115 Stat. 11 (May 24, 2001).

Database on the Internet citation (link to a specific record)

Open database:

Who's Certified [Internet]. Evanston (IL): The American Board of Medical Specialists. c2000 - [cited 2001 Mar 8]. Available at: http://www.abms.org/newsearch.asp

Closed database:

Jablonski S. Online Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes [Internet]. Bethesda (MD): National Library of Medicine (US); c1999 [updated 2001 Nov 20; cited 2002 Aug 12]. Available at: http://www.nlm.nih.gov/archive//20061212/mesh/jablonski/syndrome_title.html  

 

2.7.        Diagrams, charts, drawings, tables

2.7.1.  Tables, charts, drawing and photocopies with names and legends should be submitted on separate pages in order they appear in the manuscript.

2.7.2.  Diagrams, charts, and drawings should be submitted electronically in the following formats: «MS Excel», «Adobe Illustrator», «Corel Draw» or «MS PowerPoint». Diagrams, charts, and drawings must be allocated on separate pages, numbered in order of citation, have names and notes if necessary (all abbreviations should be expanded in the notes). Drawings must not repeat content of tables. Please indicate names and units of measurement for graph axes. Provide legend for each graph (denote lines and filling). If you compare diagrams, provide significance of differences. Do not use 3-D models for histograms. Please identify places in the text, where you wish schemes, drawings and graphs to be inserted. The text should contain links to all diagrams, charts, tables and drawings.

2.7.3.  Photographs must be submitted electronically with a minimum resolution of 300 dots per inch (dpi). Microphotos must be cropped so that only main content is left. Arrows should be used to show main features. All symbols, arrows and legends on gray-scale illustrations should be in contrast with the background.

2.7.4.  Size of legends on images and photos should be big enough to be legible after compression for publication. The optimal size is 12 points.

2.7.5.  All abbreviations should be defined either after first citation in a legend, or in alphabetic order at the end of each legend. All symbols (arrows, circles, etc.) must be explained.

2.7.6.  If data was published earlier, it is desirable* to provide a written permission from the publisher.

2.7.7.  Tables should have numbers in order of citation in the text, and names. Tables should be compact and demonstrative. Names of columns and rows must reflect the content. Data presented in tables, should not be repeated in the text or images. Please clearly specify units of measurement of variables and form of data presentation (M±m; M±SD; Me; Mo; percentiles etc.). All figures, sums and percentages must be thoroughly checked and correspond to those in the text. Explanatory footnotes should be provided below the table if necessary.

2.7.8.  Abbreviations should be listed in a footnote under the table in alphabetic order. Symbols of footnotes should be given in the following order: *, †, ‡, §, | |, ¶, #, **, † † etc.

2.7.9.  If tables were published earlier, it is desirable to provide a written permission* from the publisher.

*Hereinafter: fulfilment of the Editors recommendations will be contributed to faster editing, acceptance and publishing of submitted manuscript


2.8.        Statement on data sharing

2.8.1.  According to the recommendations of the ICMJE, when submitting an article containing data on a clinical study, the authors should submit a separate document "Statement on data sharing".

2.8.2.  In accordance with statement of the International Committee of Medical Journal Editors, as of July 1, 2018, manuscripts submitted to the journal that report the results of clinical trials must contain a data sharing statement. Clinical trials that begin enrolling participants on or after January 1, 2019, must include a data sharing plan in the trial's registration.

2.8.3.  The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration, this should be reflected in the statement submitted and published with the manuscript and updated in the registry record.

 

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. The manuscripts are accepted if has not been published or submitted for publication elsewhere.
  2. The materials should be prepared in a format OpenOffice, Microsoft Word, RTF, or World Perfect.
  3. Internet links are provided as a complete URL. 

  4. Text should be typed with an interval of one line spacing, font Times New Roman, 12 pt; to highlight the accents it is recommended to use italics rather than underlining (except Internet links). All images, graphics and tables are placed within the text according to the meaning of the particular part of text  (and not at the end of the document).
  5. Text should follow the stylistic and bibliography requirements as stated in  Regulations  located in the Part "About Us." 

  6. Please, remove the authors' names from the title of the article and other parts of the document to ensure the  anonymity of reviewing.

 

Copyright Notice

Authors who publish with this journal agree to the following terms:

  • Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

 

Privacy Statement

Specified when registering the names and addresses will be used solely for technical purposes of a contact with the Author or reviewers (editors) when preparing the article for publication. Private data will not be shared with other individuals and organizations.